AC   CVCL_0531
DR   BTO; BTO:0001620
DR   CLO; CLO_0009059
DR   CLO; CLO_0050268
DR   EFO; EFO_0003072
DR   MCCL; MCC:0000430
DR   CLDB; cl4345
DR   CLDB; cl4347
DR   CLDB; cl4348
DR   CLDB; cl4349
DR   CLDB; cl4351
DR   CLDB; cl4352
DR   AddexBio; C0005006/4924
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821600
DR   BioSample; SAMN03472879
DR   BioSample; SAMN10987849
DR   cancercelllines; CVCL_0531
DR   CCRID; 1101HUM-PUMC000086
DR   CCRID; 4201HUM-CCTCC00047
DR   Cell_Model_Passport; SIDM01098
DR   CGH-DB; 62-1
DR   CGH-DB; 9093-4
DR   ChEMBL-Cells; CHEMBL3307745
DR   ChEMBL-Targets; CHEMBL614924
DR   CLS; 305028
DR   Cosmic; 697284
DR   Cosmic; 717431
DR   Cosmic; 801743
DR   Cosmic; 848936
DR   Cosmic; 922656
DR   Cosmic; 923830
DR   Cosmic; 930078
DR   Cosmic; 947706
DR   Cosmic; 1019929
DR   Cosmic; 1037355
DR   Cosmic; 1078393
DR   Cosmic; 1082519
DR   Cosmic; 1099151
DR   Cosmic; 1109108
DR   Cosmic; 1109371
DR   Cosmic; 1153800
DR   Cosmic; 1153806
DR   Cosmic; 1162006
DR   Cosmic; 1167420
DR   Cosmic; 1167993
DR   Cosmic; 1518079
DR   Cosmic; 1526640
DR   Cosmic; 2058116
DR   Cosmic; 2131595
DR   Cosmic; 2239469
DR   Cosmic; 2393645
DR   Cosmic; 2485952
DR   Cosmic-CLP; 717431
DR   DepMap; ACH-000149
DR   ECACC; 86012802
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 717431
DR   GEO; GSM231674
DR   GEO; GSM231675
DR   GEO; GSM231676
DR   GEO; GSM231677
DR   GEO; GSM231678
DR   GEO; GSM231679
DR   GEO; GSM231680
DR   GEO; GSM231681
DR   GEO; GSM231682
DR   GEO; GSM231683
DR   GEO; GSM231684
DR   GEO; GSM231685
DR   GEO; GSM231686
DR   GEO; GSM231687
DR   GEO; GSM231688
DR   GEO; GSM231689
DR   GEO; GSM231690
DR   GEO; GSM231691
DR   GEO; GSM231692
DR   GEO; GSM231693
DR   GEO; GSM314027
DR   GEO; GSM333814
DR   GEO; GSM563357
DR   GEO; GSM692864
DR   GEO; GSM803335
DR   GEO; GSM887597
DR   GEO; GSM888680
DR   GEO; GSM923419
DR   GEO; GSM923441
DR   GEO; GSM1003626
DR   GEO; GSM1003627
DR   GEO; GSM1003628
DR   GEO; GSM1003629
DR   GEO; GSM1003630
DR   GEO; GSM1003631
DR   GEO; GSM1003632
DR   GEO; GSM1003633
DR   GEO; GSM1008585
DR   GEO; GSM1010735
DR   GEO; GSM1010738
DR   GEO; GSM1010739
DR   GEO; GSM1010750
DR   GEO; GSM1010751
DR   GEO; GSM1010763
DR   GEO; GSM1010767
DR   GEO; GSM1010773
DR   GEO; GSM1010799
DR   GEO; GSM1010806
DR   GEO; GSM1010816
DR   GEO; GSM1010817
DR   GEO; GSM1010834
DR   GEO; GSM1010835
DR   GEO; GSM1010840
DR   GEO; GSM1010858
DR   GEO; GSM1010880
DR   GEO; GSM1010887
DR   GEO; GSM1010897
DR   GEO; GSM1010900
DR   GEO; GSM1010901
DR   GEO; GSM1622296
DR   GEO; GSM1670454
DR   GEO; GSM2371259
DR   GEO; GSM2394365
DR   GEO; GSM2824362
DR   GEO; GSM2824363
DR   GEO; GSM4104597
DR   GEO; GSM4104598
DR   GEO; GSM4104637
DR   GEO; GSM4104638
DR   IARC_TP53; 23584
DR   ICLC; HTL96019
DR   KCB; KCB 200426YJ
DR   KCLB; 30011
DR   Lonza; 80
DR   PharmacoDB; SKNSH_1409_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0531
DR   PubChem_Cell_line; CVCL_0531
DR   RCB; RCB0426
DR   TOKU-E; 3149
DR   Ubigene; YC-C027
DR   Wikidata; Q28308636
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   DOI=10.1159/000407025;
RX   PubMed=29704;
RX   PubMed=62055;
RX   PubMed=833871;
RX   PubMed=922665;
RX   PubMed=1354203;
RX   PubMed=2535691;
RX   PubMed=2846152;
RX   PubMed=2987426;
RX   PubMed=3518877;
RX   PubMed=4748425;
RX   PubMed=6582512;
RX   PubMed=6610792;
RX   PubMed=6888561;
RX   PubMed=6935474;
RX   PubMed=7037175;
RX   PubMed=7838528;
RX   PubMed=8040301;
RX   PubMed=8069455;
RX   PubMed=8490657;
RX   PubMed=8617485;
RX   PubMed=8665486;
RX   PubMed=10074188;
RX   PubMed=10630978;
RX   PubMed=11550280;
RX   PubMed=12702577;
RX   PubMed=15390183;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=18957096;
RX   PubMed=18923523;
RX   PubMed=18923524;
RX   PubMed=22213050;
RX   PubMed=22460905;
RX   PubMed=23325432;
RX   PubMed=24466371;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-529.
CC   Population: Caucasian.
CC   Doubling time: 44 hours (PubMed=4748425).
CC   HLA typing: A*01:01,24:02; B*18:01,49:01; C*07:06,07:06 (PubMed=25960936).
CC   HLA typing: A*01:01,24:02; B*18:01,49:01; C*07:06,07:06 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18724359; PubMed=18923523; PubMed=28350380; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: ChIP-seq epigenome analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.37%; Native American=0.07%; East Asian, North=1.63%; East Asian, South=0%; South Asian=0%; European, North=66.77%; European, South=31.16% (PubMed=30894373).
CC   Misspelling: SK-N-CH; Note=Occasionally.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 14
ST   D12S391: 18,22
ST   D13S317: 11
ST   D16S539: 8,13
ST   D18S51: 13,16
ST   D19S433: 13,14
ST   D1S1656: 12
ST   D21S11: 31,31.2
ST   D22S1045: 16,17
ST   D2S1338: 17,19
ST   D2S441: 11,11.3
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 7,10
ST   D8S1179: 15
ST   FGA: 23.2,24
ST   Penta D: 10,12
ST   Penta E: 7,11
ST   TH01: 7,10
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   4Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 45
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
RX   DOI=10.1159/000407025;
RA   Helson L., Verma M., Helson C.;
RT   "Vitamin E and human neuroblastoma.";
RL   (In) Modulation and mediation of cancer by vitamins; Meyskens F.L., Prasad K.N. (eds.); pp.258-265; Karger; Basel (1983).
RX   PubMed=29704;
RA   Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.;
RT   "Multiple neurotransmitter synthesis by human neuroblastoma cell lines
RT   and clones.";
RL   Cancer Res. 38:3751-3757(1978).
RX   PubMed=62055; DOI=10.1093/jnci/57.3.683;
RA   Biedler J.L., Spengler B.A.;
RT   "A novel chromosome abnormality in human neuroblastoma and
RT   antifolate-resistant Chinese hamster cell lives in culture.";
RL   J. Natl. Cancer Inst. 57:683-695(1976).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1;
RA   Brodeur G.M., Sekhon G., Goldstein M.N.;
RT   "Chromosomal aberrations in human neuroblastomas.";
RL   Cancer 40:2256-2263(1977).
RX   PubMed=1354203; DOI=10.1002/ijc.2910520116;
RA   Gross N., Favre S., Beck D., Meyer M.;
RT   "Differentiation-related expression of adhesion molecules and
RT   receptors on human neuroblastoma tissues, cell lines and variants.";
RL   Int. J. Cancer 52:85-91(1992).
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
RX   PubMed=2846152;
RA   Preis P.N., Saya H., Nadasdi L., Hochhaus G., Levin V., Sadee W.;
RT   "Neuronal cell differentiation of human neuroblastoma cells by
RT   retinoic acid plus herbimycin A.";
RL   Cancer Res. 48:6530-6534(1988).
RX   PubMed=2987426; DOI=10.1007/BF00165170;
RA   Helson L., Helson C.;
RT   "Human neuroblastoma cells and 13-cis-retinoic acid.";
RL   J. Neurooncol. 3:39-41(1985).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4748425;
RA   Biedler J.L., Helson L., Spengler B.A.;
RT   "Morphology and growth, tumorigenicity, and cytogenetics of human
RT   neuroblastoma cells in continuous culture.";
RL   Cancer Res. 33:2643-2652(1973).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=6610792; DOI=10.1093/jnci/73.1.51;
RA   Sugimoto T., Tatsumi E., Kemshead J.T., Helson L., Green A.A.,
RA   Minowada J.;
RT   "Determination of cell surface membrane antigens common to both human
RT   neuroblastoma and leukemia-lymphoma cell lines by a panel of 38
RT   monoclonal antibodies.";
RL   J. Natl. Cancer Inst. 73:51-57(1984).
RX   PubMed=6888561; DOI=10.1038/305245a0;
RA   Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M.,
RA   Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.;
RT   "Amplified DNA with limited homology to myc cellular oncogene is
RT   shared by human neuroblastoma cell lines and a neuroblastoma tumour.";
RL   Nature 305:245-248(1983).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
RX   PubMed=8040301; DOI=10.1172/JCI117360;
RA   Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.H., Nycum L.,
RA   Emanuel B.S., Evans G.A.;
RT   "EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and
RT   primitive neuroectodermal tumors with variant translocations.";
RL   J. Clin. Invest. 94:489-496(1994).
RX   PubMed=8069455; DOI=10.1007/BF02631450;
RA   Fukuchi K.-I., Hearn M.G., Deeb S.S., Smith A.C., Dang N.,
RA   Miyazaki J.-I., Bothwell M., Martin G.M.;
RT   "Activity assays of nine heterogeneous promoters in neural and other
RT   cultured cells.";
RL   In Vitro Cell. Dev. Biol. Anim. 30:300-305(1994).
RX   PubMed=8490657; DOI=10.1038/ng0193-62;
RA   The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G.,
RA   Gusella J.F., Bernards A.;
RT   "Neurofibromatosis type 1 gene mutations in neuroblastoma.";
RL   Nat. Genet. 3:62-66(1993).
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
RX   PubMed=10074188; DOI=10.1128/JVI.73.4.3338-3350.1999;
RA   Arbour N., Cote G., Lachance C., Tardieu M., Cashman N.R.,
RA   Talbot P.J.;
RT   "Acute and persistent infection of human neural cell lines by human
RT   coronavirus OC43.";
RL   J. Virol. 73:3338-3350(1999).
RX   PubMed=10630978; DOI=10.1667/0033-7587(2000)153[0062:FORIMI]2.0.CO;2;
RA   Akudugu J.M., Slabbert J.P., Serafin A., Bohm L.;
RT   "Frequency of radiation-induced micronuclei in neuronal cells does not
RT   correlate with clonogenic survival.";
RL   Radiat. Res. 153:62-67(2000).
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
RX   PubMed=18957096; DOI=10.1186/1756-0500-1-95;
RA   Nishida Y., Adati N., Ozawa R., Maeda A., Sakaki Y., Takeda T.;
RT   "Identification and classification of genes regulated by
RT   phosphatidylinositol 3-kinase- and TRKB-mediated signalling pathways
RT   during neuronal differentiation in two subtypes of the human
RT   neuroblastoma cell line SH-SY5Y.";
RL   BMC Res. Notes 1:95.1-95.11(2008).
RX   PubMed=18923523; DOI=10.1038/nature07398;
RA   Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A.,
RA   de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G.,
RA   Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S.,
RA   Amiel J., Delattre O.;
RT   "Somatic and germline activating mutations of the ALK kinase receptor
RT   in neuroblastoma.";
RL   Nature 455:967-970(2008).
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L.,
RA   Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H.,
RA   Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).